Back to News & Events

Long Island Bioscience Hub Reports Significant Impacts

Phase 0 Proof-of-Concept Partnership pilot program demonstrates effectiveness for
transitioning basic science discoveries into the commercialization pipeline.

The Long Island Bioscience Hub (LIBH), a National Institutes of Health (NIH) Research Evaluation and Commercialization Hub (REACH), is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. The LIBH, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, led by the Center for Biotechnology, was formed in March 2015 with a mission to help commercialize biomedical technologies emerging from the region’s research institutions.

The report, prepared independently by RTI International on behalf of the NIH, outlines multiple outcomes from the REACH program, and documents the successes that the LIBH has had during the relatively short pilot phase of its work. The LIBH engaged 600 innovators in training sponsored or co-sponsored by the REACH Program. Fifty technology development projects have been funded by LIBH over the course of three years, including technologies focused on biologic drugs, diagnostic devices, small molecule drugs, therapeutic devices, and Health IT among others. As a result of the NIH investment in the LIBH, ten startup companies have been formed and two license agreements have been executed. In addition, the initial investment made by NIH in the region has generated follow on funding of more than $10 million, $2.8 million coming from five funded SBIR/STTR proposals based on LIBH technologies. This impact from the REACH program contributes to the overall economic impact of Center for Biotechnology, notably $1.2B over a recent fifteen year period.

“We are thrilled with the outcomes reported in the RTI evaluation for the Long Island Bioscience Hub’s efforts thus far under the REACH program” said Clinton T. Rubin, Ph.D., Distinguished Professor, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Through the REACH program we’ve been able to expand on the region’s efforts to commercialize more innovation locally, thereby capturing more of the economic impact within the region. While the pilot program will end in mid-2019, these impacts clearly demonstrate the potential of the model to make significant contributions to our innovation ecosystem.”

“The RTI evaluation reinforces our knowledge that the Long Island Bioscience Hub model has already had a significant, positive impact on technologies and innovators embedded in our research community” stated Dr. Richard Reeder, Vice President for Research at Stony Brook University. “It is imperative we continue to fuel the activities of the LIBH as it is an essential part of innovation economy, and is a significant engine in bringing lifesaving technologies to patients.”

The Center for Biotechnology, in collaboration with other partners in the region, will continue to explore how the model might be continued and expanded.

Click here for PDF version.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4906
                    [post_author] => 4
                    [post_date] => 2025-07-17 10:27:09
                    [post_date_gmt] => 2025-07-17 14:27:09
                    [post_content] => 

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4002 [post_author] => 4 [post_date] => 2022-02-10 14:41:00 [post_date_gmt] => 2022-02-10 14:41:00 [post_content] =>

Center for Biotechnology's Director of Operations, Diane Fabel recently penned an OpEd for the Long Island Business News: "Biotech investments, partnerships key to LI economy".

"Breakthroughs made by academic and industry scientists over the last 20 years have advanced the field of biomedicine exponentially. Immunotherapies, regenerative medicine, and pre-symptomatic diagnostics are now realities.

Long Island is facing a moment of enormous potential to advance biomedical discoveries that will improve human health and drive economic growth. Enabled by a concentration of world-class research institutions, and an emerging bioscience industry cluster, the region is at a tipping point."

Read the full article on LIBN.com

[post_title] => CFB's Diane Fabel: Biotech investments, partnerships key to LI economy [post_excerpt] => Center for Biotechnology's Director of Operations, Diane Fabel recently penned an OpEd for the Long Island Business News: "Biotech investments, partnerships key to LI economy" [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cfbs-diane-fabel-biotech-investments-partnerships-key-to-li-economy [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:38:42 [post_modified_gmt] => 2024-08-22 15:38:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4002 [menu_order] => 15 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4929 [post_author] => 4 [post_date] => 2026-02-16 13:07:36 [post_date_gmt] => 2026-02-16 18:07:36 [post_content] =>

In early February, we welcomed leadership from Empire State Development (ESD), including its Division of Science, Technology and Innovation (NYSTAR) and New York Ventures, for a two-day visit focused on applied research, industry collaboration and economic development across New York State.

The visit spotlighted key teams throughout Stony Brook University, including the Center’s role in driving innovation through supporting hundreds of patents, licenses, and commercialization efforts to help translate breakthrough discoveries into real‑world medical and biotechnology applications. As our very own Clinton Rubin remarked, "We are excited by NYS’s commitment to harnessing Stony Brook’s research enterprise for economic impact, and building the life sciences innovation and entrepreneurship ecosystem here on campus, on Long Island and in our State.”

We’re excited to share more soon about how our Center is bringing its vision to life by accelerating the path from academic research to marketplace solutions.

[post_title] => NYSTAR Visits SBU [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nystar-visits-sbu [to_ping] => [pinged] => [post_modified] => 2026-03-09 13:25:51 [post_modified_gmt] => 2026-03-09 17:25:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4929 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 4477 [post_author] => 4 [post_date] => 2024-09-10 13:59:15 [post_date_gmt] => 2024-09-10 17:59:15 [post_content] =>

Established in April 2023, Stony Brook University's Center for Healthy Aging aims to promote healthy aging and extend physical and mental well-being through innovative research solutions. Please join them for our inaugural virtual seminar series.

Dr. Payel Sen, Stadtman Investigator, NIH
Epigenetic mechanisms of tissue aging
September 25th at 11 am
https://stonybrook.zoom.us/j/98037022918?pwd=XT2p35EKbehaazZpb0aLJtOW3a8gE1.1
Meeting ID: 980 3702 2918
Passcode: 426599

As we age, changes in our “epigenome” alter how our genes are regulated, ultimately impacting organ function. Our research focuses on understanding epigenomic changes in different organs. In this presentation, I will focus on skeletal muscle, which makes up 40% of our body weight and plays a key role in metabolism. As we age, our muscles tend to weaken, partly because the stem cells in our muscles that help repair and grow reduce in number and function. In our study, we looked at muscle stem cells from young, old, and geriatric mice and uncovered that as these cells age, they show signs of increased immune activity and start to lose their ability to stay dormant, which is vital for their function. We also identified specific areas of the genome that might be responsible for these changes. By targeting these areas, we could potentially restore the function of these stem cells and help maintain muscle health as we age.

Upcoming Topics & Dates:

  • October 30th, 11 am: Samantha Rossano, PhD, Medical Science Liaison, Life Molecular Imaging, Inc., Brain imaging biomarkers in Alzheimer’s disease
  • November 20th, 11 am: Gregorio Valdez, PhD, GLF Translational Associate Professor of Molecular Biology, Cell Biology and Biochemistry, Brown University, Slowing muscle degeneration
  • February 26th, 11 am: Christopher Barrett Bowling, MD, MSPH, Associate Professor of Medicine, Associate Professor in Population Health Sciences, Senior Fellow of the Center for the Study of Aging and Human Development, Duke University, Geriatricizing chronic disease research
  • March 26th, 11 am: Dr. Frank Lin, MD, PhD, Director of the Cochlear Center for Hearing and Public Health, Professor of Otolaryngology, Medicine, Mental Health, and Epidemiology, Johns Hopkins University Team, Baltimore HEARS and the Baltimore Longitudinal Study of Aging
  • April 30th, 11 am: Dennis Selkoe, MD, Vincent and Stella Coates Professor of Neurologic Diseases, Harvard University, Role of soluble oligomers of amyloid beta in synaptic injury

[post_title] => SBU Center for Healthy Aging Seminar Series [post_excerpt] => Join Stony Brook's Center for Healthy Aging for their inaugural virtual seminar series. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => https-centerforbiotechnology-org-sbu-cha-seminar-series [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:36:33 [post_modified_gmt] => 2024-12-05 16:36:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4477 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 5 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4906 [post_author] => 4 [post_date] => 2025-07-17 10:27:09 [post_date_gmt] => 2025-07-17 14:27:09 [post_content] =>

The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.

The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.

“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”

Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”

The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.

“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.

As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.

Dowload the full press release here.

[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => redesignation2025 [to_ping] => [pinged] => [post_modified] => 2025-07-21 14:51:44 [post_modified_gmt] => 2025-07-21 18:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4906 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 281 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology

More Information

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

CFB’s Diane Fabel: Biotech investments, partnerships key to LI economy

More Information

NYSTAR Visits SBU

More Information

SBU Center for Healthy Aging Seminar Series

More Information